Immunoprecise Antibodies Ltd Share Price Other OTC
Equities
CA87588T1030
Pharmaceuticals
Sales 2024 * | 2.46Cr 1.8Cr 149.81Cr | Sales 2025 * | 2.98Cr 2.18Cr 181.67Cr | Capitalization | 3.64Cr 2.66Cr 221.63Cr |
---|---|---|---|---|---|
Net income 2024 * | -1.2Cr -87.66L -73Cr | Net income 2025 * | -90L -65.74L -55Cr | EV / Sales 2024 * | 1.48 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.22 x |
P/E ratio 2024 * |
-2.88
x | P/E ratio 2025 * |
-3.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.41% |
Latest transcript on Immunoprecise Antibodies Ltd
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21/18/21 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 29/23/29 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 05/23/05 |
Jennifer Bath
CEO | Chief Executive Officer | - | 21/18/21 |
1st Jan change | Capi. | |
---|---|---|
+2.99% | 9.52TCr | |
-4.34% | 3.75TCr | |
-10.41% | 3.38TCr | |
+75.79% | 2.82TCr | |
-14.61% | 1.56TCr | |
-3.46% | 1.36TCr | |
-12.31% | 1.15TCr | |
+184.77% | 1.08TCr | |
-54.13% | 923.34Cr |